Experimental combo tackles tough cancers: early results show promise

NCT ID NCT03184870

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 23 times

Summary

This study tested an experimental drug called BMS-813160, given alone or with chemotherapy and/or the immunotherapy nivolumab, in 332 people with advanced colorectal or pancreatic cancer. The main goals were to check safety and side effects, and to see if the drug combination could shrink tumors. The study is complete, and results help guide future research on these hard-to-treat cancers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Local Institution - 0001

Toronto, Ontario, M5G 1X6, Canada
Local Institution - 0002

Los Angeles, California, 90033, United States
Local Institution - 0003

Birmingham, Alabama, 35249, United States
Local Institution - 0004

Hackensack, New Jersey, 07601, United States
Local Institution - 0005

Baltimore, Maryland, 21287, United States
Local Institution - 0007

Heidelberg, 69120, Germany
Local Institution - 0012

Ottawa, Ontario, K1H 8L6, Canada
Local Institution - 0013

Edmonton, Alberta, T6G 1Z2, Canada
Local Institution - 0014

Philadelphia, Pennsylvania, 19104, United States
Local Institution - 0015

Aurora, Colorado, 80045, United States
Local Institution - 0016

Salt Lake City, Utah, 84112, United States
Local Institution - 0017

New York, New York, 10065, United States
Local Institution - 0018

Washington D.C., District of Columbia, 20007, United States
Local Institution - 0020

Philadelphia, Pennsylvania, 19107, United States
Local Institution - 0021

Cleveland, Ohio, 44195, United States
Local Institution - 0022

Dresden, 01307, Germany
Local Institution - 0023

St Louis, Missouri, 63110, United States
Local Institution - 0024

Rochester, New York, 14642, United States
Local Institution - 0025

Los Angeles, California, 90033, United States
Local Institution - 0026

Phoenix, Arizona, 85054, United States
Local Institution - 0027

Rochester, Minnesota, 55905-0001, United States
Local Institution - 0028

Clayton, Victoria, 0, Australia
Local Institution - 0030

Majadahonda - Madrid, 28222, Spain
Local Institution - 0031

Barcelona, 08003, Spain
Local Institution - 0032

Madrid, 28046, Spain
Local Institution - 0033

Boston, Massachusetts, 02114, United States
Local Institution - 0034

Nashville, Tennessee, 37203, United States
Local Institution - 0037

Allentown, Pennsylvania, 18103, United States
Local Institution - 0038

Nashville, Tennessee, 37232, United States
Local Institution - 0039

Hattiesburg, Mississippi, 39401, United States
Local Institution - 0041

Orange, California, 92868-3201, United States
Local Institution - 0042

Charlottesville, Virginia, 22908, United States
Local Institution - 0044

Cleveland, Ohio, 44106-5055, United States
Local Institution - 0045

Charleston, South Carolina, 29425, United States
Local Institution - 0046

Charlotte, North Carolina, 28204, United States
Local Institution - 0047

St. Petersburg, Florida, 33705, United States
Local Institution - 0048

Brooksville, Florida, 34613, United States
Local Institution - 0049

Leuven, 3000, Belgium
Local Institution - 0050

Brussels, 1200, Belgium
Local Institution - 0051

Edegem, 2650, Belgium

Conditions

Explore the condition pages connected to this study.

COLORECTAL CANCER PANCREATIC CANCER